Complement Targeted Therapeutics Market Size, Share | 2032

Report Description

Complement Targeted Therapeutics Market Outlook 2032

The global complement targeted therapeutics market size was USD 8.08 Billion in 2023 and is projected to reach USD 20.17 Billion by 2032, expanding at a CAGR of 10.7% during 2024–2032. The market growth is attributed to the increasing demand for precision medicine solutions across the globe.

Increasing demand for precision medicine solutions is fueling the complement targeted therapeutics market. Complement-targeted therapies find applications in biotechnology, immunotherapy, and gene editing, due to their versatility and effectiveness across different therapeutic modalities. Additionally, the aged population and changing lifestyle factors contribute to the escalating burden of complement-mediated diseases, further boosting the demand for targeted therapies.

• According to the report published by the WHO on October 1, 2022, the global population of people aged 60 years and older is projected to double by 2050, reaching 2.1 billion.
  

  Get Free Sample Report
  

Impact of Artificial Intelligence (AI) in the Complement Targeted Therapeutics Market

The use of artificial intelligence is likely to boost the complement targeted therapeutics market. AI-driven platforms analyze vast datasets, including genetic profiles, protein structures, and disease pathways to facilitate the development of effective complement-targeted therapies. Furthermore, AI-driven diagnostic tools aid in early disease detection and personalized treatment selection while optimizing patient outcomes and reducing healthcare costs.

Complement Targeted Therapeutics Market Dynamics

Get Free Sample Report

Major Drivers

Increasing prevalence of complement-mediated diseases, such as autoimmune disorders and inflammatory conditions, is anticipated to drive the market during the forecast period. Growing incidence of diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis necessitates effective treatment options targeting the dysregulated complement system.

The report published by the WHO on June 28, 2023, reveals that in 2019, 18 million people across the globe were living with rheumatoid arthritis. Additionally, surging demand for biologics and targeted therapies is driving the adoption of complement-targeted therapeutics.

Existing Restraints

High costs associated with complement-targeted therapeutics and limited reimbursement options are projected to hinder the market in the coming years. Development of novel complement-targeted drugs requires substantial investments in research & development, clinical trials, and manufacturing processes.

Increasing research & development, clinical trials, and manufacturing processes lead to high product pricing to recoup expenses affecting their widespread adoption across the healthcare sectors. Furthermore, increasing regulatory challenges and stringent approval processes further hamper the market.

Emerging Opportunities

­Growing investment in biomedical research and development is expected to create immense opportunities for the players competing in the market during the forecast period. Pharmaceutical companies are focusing on developing new precision medicine and personalized healthcare solutions.

They are investing in the discovery and development of complement-targeted drugs tailored to specific patient populations. Moreover, government initiatives and funding support the molecular mechanisms of complement dysregulation research projects to further boost the market.

Scope of the Complement Targeted Therapeutics Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Complement Targeted Therapeutics Market Segment Insights

Type Segment Analysis

Based on type, the complement targeted therapeutics market is divided into atypical haemolytic uraemic syndrome, paroxysmal nocturnal haemoglobinuria, and others. The paroxysmal nocturnal haemoglobinuria (PHN) segment held a major share of the market in 2023, due to the high prevalence of PNH.

Complement-targeted therapies, such as eculizumab (Soliris) are being widely used for the management of PNH. They effectively inhibit complement-mediated hemolysis and reducing the risk of associated complications. Moreover, advancements in diagnostic techniques and increased awareness of PNH among healthcare professionals further boost the segment.

The atypical haemolytic uraemic syndrome segment is expected to expand at a significant growth rate in the coming years, owing to the ongoing development of novel complement-targeted therapies specifically tailored for this condition. Pharmaceuticals are utilizing drugs targeting complement component C5, such as eculizumab and ranibizumab to introduce these novel treatment solutions. Moreover, the increasing awareness initiatives and improved diagnostic capabilities facilitating early diagnostics and interventions further boosted the demand for the complement targeted therapeutics.

Get Free Sample Report

Distribution Channel Segment Analysis

On the basis of distribution Channel, the global market is segregated into retail pharmacies, hospitals pharmacies, online pharmacies, and others. The online pharmacies segment is anticipated to expand at a substantial CAGR during the forecast period, due to the increasing adoption of digital healthcare platforms and e-commerce channels.

Online pharmacies offer the advantage of doorstep delivery and 24/7 accessibility to patients with chronic conditions requiring regular medication refills. Moreover, the growing popularity of telemedicine services facilitating remote prescribing and medication management further fuels the demand for complement-targeted therapies through online channels.

Route of Administration Segment Analysis

Based on route of administration, the complement targeted therapeutics market is segmented into oral or subcutaneous forms and intravenous. The intravenous segment led the market in terms of revenue in 2023, due to the high efficacy of intravenous formulations of complement-targeted drugs.

IV administration allows for direct delivery of therapeutic agents into the bloodstream for maximum bioavailability. Moreover, the availability of established infusion centers and experienced healthcare professionals proficient in IV administration further boosts the segment during the forecast period.

The subcutaneous route to administration segment is projected to register a robust growth rate during the assessment years, as they offer convenience and reduced healthcare resource utilization over intravenous infusion. Moreover, the availability of user-friendly injection devices and autoinjectors simplifies the administration process further boosting the demand for the subcutaneous route to administration.

Get Free Sample Report

Regional Outlook

In terms of region, the global complement targeted therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. North America held a major market share in 2023, due to the presence of robust research and development infrastructure.

This region is at the forefront of biomedical research and innovation which focuses on developing new complement targeted therapies. Moreover, the growing prevalence of complement-mediated diseases, such as autoimmune disorders and chronic inflammatory conditions further propels the market in this region.

• According to the report published by the Yale School of Medicine on May 16, 2022, the autoimmunity prevalence is rising in the US. Researchers found a 44% increase in ANA, the autoantibody targeting self in lupus, in the last 25 years further affecting 41 million people.

The market in Asia Pacific is projected to expand at a significant pace in the years to come, owing to the rising incidence of autoimmune diseases. Countries, such as China, India, and Japan are witnessing a surge in the prevalence of autoimmune disorders and inflammatory conditions, creating a large patient pool for effective complement-targeted therapies. Moreover, the presence of a large population base and growing awareness of personalized healthcare solutions is further boosting the demand for the complement targeted therapies in this region.

Get Free Sample Report